Angiotensinogen (serpin Peptidase Inhibitor, Clade A, Member 8) (AGT) Peptide
-
- Target See all AGT products
- AGT (Angiotensinogen (serpin Peptidase Inhibitor, Clade A, Member 8) (AGT))
- Origin
- Human
-
Source
- Synthetic
- Application
- Western Blotting (WB), Blocking Peptide (BP)
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-AGT antibody (Catalog #: ARP43614_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- AGT (Angiotensinogen (serpin Peptidase Inhibitor, Clade A, Member 8) (AGT))
- Synonyms
- ANHU Peptide, SERPINA8 Peptide, AI265500 Peptide, AngI Peptide, AngII Peptide, Aogen Peptide, Serpina8 Peptide, ANRT Peptide, Ang Peptide, PAT Peptide, wu:fb62f06 Peptide, wu:fj87b02 Peptide, zgc:111892 Peptide, AGT Peptide, angt Peptide, ANGT Peptide, angiotensinogen Peptide, angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Peptide, AGT Peptide, Agt Peptide, agt Peptide
- Background
-
AGT, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure and in the pathogenesis of essential hypertension and preeclampsia. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease.The protein encoded by this gene, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure and in the pathogenesis of essential hypertension and preeclampsia. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.
Alias Symbols: ANHU, SERPINA8
Protein Interaction Partner: ACE2,AGT,AGTR1,AGTR2,CMA1,CTSG,DNPEP,ENPEP,EWSR1,KNG1,MAS1,MEP1A,PRCP,PREP,PRG2,EWSR1
Protein Size: 485 - Molecular Weight
- 53 kDa
- Gene ID
- 183
- NCBI Accession
- NM_000029, NP_000020
- UniProt
- P01019
-